Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel

Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel Ahmedabad, India, 07 June, 2022 Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), has received final approval from the United States Food and Drug Administration (USFDA) to market Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5% (USRLD: Epiduo Forte ). A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples . Adapalene works by affecting the growth of cells and decreasing swelling and inflammation and Benzoyl Peroxide works by reducing the amount of acne-causing bacteria and by causing the skin to dry and peel off. The drug will be manufactured at group’s topical facility at Ahmedabad. Adapalene and Benzoyl Peroxide Topical Gel had a market size of USD 195 mn (as per IQVIA MAT April 22). The group now has 315 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04. About Zydus The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapie s. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life - sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com. (*as of 31st March 2022) ****

The release as fetched from its publisher. zyduslife.com ↗